Clinical trials: Uterus Cancer
Cervix Cancer, Endometrial Cancer
Bone Marrow Sparing Image-Guided Radiation Therapy (RT) Incorporating Novel Use of GCSF and FDG-PET Imaging
This is a research study using Granulocyte Colony Stimulating Factor (GCSF) as a bone marrow stimulating agent for imaging to guide radiation treatment planning. G-CSF is a type of growth factor.
- Trial name
- NCT04514692
- Testing
- GCSF
- Where
- United States
- Volunteers
- 7 people
- Sponsor
- Stanford University
Endometrial Cancer, Cervical Cancer
Determining the Sensitivity of Sentinel Lymph Nodes Identified With Robotic Fluorescence Imaging
Description: This is a multi-institutional study investigating the sensitivity and negative predictive value of sentinel lymph nodes mapped with robotic assisted near infrared imaging after cervical injection of indocyanine green…
- Trial name
- FIRES (NCT01673022)
- Testing
- IC Green
- Where
- 7 sites in United States
- Volunteers
- 430 people
- Sponsor
- Indiana University
Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive
DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine INO-3112 and Durvalumab in Treating Patients With Recurrent or Metastatic Human Papillomavirus Associated Cancers
This phase II trial studies how well deoxyribonucleic acid (DNA) plasmid-encoding interleukin-12/human papillomavirus (HPV) DNA plasmids therapeutic vaccine INO-3112 and durvalumab work in treating patients with human…
- Conditions
- Human Papillomavirus-16 Positive, Human Papillomavirus-18 Positive, Metastatic Malignant Neoplasm, Recurrent Anal Canal Carcinoma
- Trial name
- NCT03439085
- Testing
- DNA Plasmid-encoding Interleukin-12/HPV DNA Plasmids Therapeutic Vaccine MEDI0457, Durvalumab
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- M.D. Anderson Cancer Center
Breast Cancer, Ovarian Cancer
FPA150 in Patients With Advanced Solid Tumors
This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1…
- Conditions
- Breast Cancer, Ovarian Cancer, Endometrial Cancer, Advanced Solid Tumors
- Trial name
- FPA150-001 (NCT03514121)
- Testing
- FPA150, Pembrolizumab
- Where
- 18 sites in United States, South Korea
- Volunteers
- 95 people
- Sponsor
- Five Prime Therapeutics, Inc.
HPV16 Associated Cervical Cancer
Safety and Feasibility of TA-CIN Vaccine in HPV16 Associated Cervical Cancer
This study will be looking at what dose of the TA-CIN vaccine is safe and effective in patients with a history of HPV16-associated cervical cancer.
- Trial name
- NCT02405221
- Testing
- TA-CIN (arm), TA-CIN (thigh)
- Where
- 2 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Cervical Cancer, Endometrial Cancer
Safety Study Of Avastin And Pelvic Radiation In Women With Recurrent Gynecological Cancers
This research study is evaluating a drug called avastin in combination with standard radiation as a possible treatment for treatment for recurrent pelvic-confined gynecological cancer (i.e.
- Conditions
- Cervical Cancer, Endometrial Cancer, Ovarian Cancer, Vaginal Cancer
- Trial name
- NCT00545792
- Testing
- Avastin
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- Dana-Farber Cancer Institute
Endometrial Cancer, Mismatch Repair-Proficient
Study of Lenvatinib w/ Pembro in Black Participants w/Mismatch Repair-Prof Recurrent Endometrial Cancer
Determine the efficacy of the combination of lenvatinib and pembrolizumab in Black participants
- Conditions
- Endometrial Cancer, Mismatch Repair-Proficient, Recurrent Endometrial Cancer
- Trial name
- NCT05263492
- Testing
- Lenvatinib, Pembrolizumab
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Virginia Commonwealth University
Papillomavirus Infections
GARDASIL™ Study in Healthy Females Between 9 and 26 Years of Age in Sub-Saharan Africa (V501-046)
The study is designed to determine the safety, tolerability and immunogenicity of a 3-dose regimen of GARDASIL™ administered to healthy females between 9 and 26 years of age, in Sub-Saharan Africa.
- Trial name
- NCT01245764
- Testing
- Quadrivalent Human Papillomavirus (Types 6, 11, 16, 18) Recombinant Vaccine (GARDASIL™)
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Endometrial Neoplasms
A Study Of Two Dual PI3K/mTOR Inhibitors, PF-04691502 And PF-05212384 In Patients With Recurrent Endometrial Cancer
This study will investigate the individual safety and efficacy of two dual PI3K/mTOR inhibitors in patients with recurrent endometrial cancer.
- Trial name
- NCT01420081
- Testing
- PF-05212384
- Where
- 51 sites in United States, Australia and 6 more
- Volunteers
- 67 people
- Sponsor
- Pfizer
Colorectal Cancer, Bladder Cancer
Feasibility Testing of Patient Reported Outcomes - Informed Symptom Management System (PRISMS)
This is a proof-of-concept pilot randomized clinical trial to test the feasibility of the innovative Patient-Reported Outcomes-Informed Symptom Management System (PRISMS) to enhance personalized supportive care for cancer…
- Conditions
- Colorectal Cancer, Bladder Cancer, Ovarian Cancer, Cervical Cancer
- Trial name
- PRISMS (NCT04492007)
- Testing
- Patient-Reported Outcomes-Informed Symptom Management System (PRISMS)
- Where
- United States
- Volunteers
- 46 people
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab, cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients with endometrial cancer that has come back…
- Conditions
- Endometrial Adenocarcinoma, Endometrial Mixed Cell Adenocarcinoma, Endometrial Serous Adenocarcinoma, Endometrial Undifferentiated Carcinoma
- Trial name
- NCT03660826
- Testing
- Biospecimen Collection, Bone Marrow Aspirate, Bone Marrow Biopsy
- Where
- 761 sites in United States, Canada
- Volunteers
- 288 people
- Sponsor
- National Cancer Institute (NCI)
Ovarian Carcinoma, Endometrial Carcinoma
Study of KPT-330 (Selinexor) in Female Patients With Advanced Gynaecologic Malignancies
The primary trial objective is to determine the efficacy of KPT-330 (selinexor) in participants with advanced or metastatic gynaecological cancers by disease control rate (complete response (CR) or partial response (PR) or stable…
- Conditions
- Ovarian Carcinoma, Endometrial Carcinoma, Cervical Carcinoma
- Trial name
- SIGN (NCT02025985)
- Testing
- Selinexor
- Where
- 4 sites in Belgium, Denmark
- Volunteers
- 116 people
- Sponsor
- Karyopharm Therapeutics Inc
Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma
Cabozantinib and Temozolomide for the Treatment of Unresectable or Metastatic Leiomyosarcoma or Other Soft Tissue Sarcoma
This phase II trial studies how well cabozantinib and temozolomide work in treating patients with leiomyosarcoma or other soft tissue sarcoma that cannot be removed by surgery (unresectable) or has spread to other places in the…
- Conditions
- Metastatic Leiomyosarcoma, Metastatic Soft Tissue Sarcoma, Stage III Uterine Corpus Leiomyosarcoma AJCC v8, Stage IIIA Uterine Corpus Leiomyosarcoma AJCC v8
- Trial name
- NCT04200443
- Testing
- Cabozantinib, Quality-of-Life Assessment, Questionnaire Administration
- Where
- 5 sites in United States
- Volunteers
- 96 people
- Sponsor
- City of Hope Medical Center
Breast Cancer, Prostate Cancer
Survivorship Promotion In Reducing IGF-1 Trial
This is a prospective, single-center randomized trial with three arms, and an allocation ratio of 1:1:1. The study design is an efficacy study to evaluate the effect of metformin and coach-directed behavioral weight loss versus…
- Conditions
- Breast Cancer, Prostate Cancer, Lung Cancer, Colon Cancer
- Trial name
- SPIRIT (NCT02431676)
- Testing
- Metformin, Coach Directed Behavioral Weight Loss, Self-control weight loss
- Where
- United States
- Volunteers
- 121 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Female Reproductive System Neoplasm, Malignant Female Reproductive System Neoplasm
EHealth Mindful Movement and Breathing in Improving Outcomes in Participants Undergoing Gynecologic Surgery
This trial determines how well eHealth mindful movement and breathing works to improve outcomes in participants undergoing gynecologic surgery.
- Conditions
- Female Reproductive System Neoplasm, Malignant Female Reproductive System Neoplasm, Malignant Uterine Neoplasm, Ovarian Carcinoma
- Trial name
- NCT03379376
- Testing
- Questionnaire Administration, Supportive Care
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- Wake Forest University Health Sciences
Endometrial Cancer
A Study of Ixabepilone as Second-line Therapy for Locally Advanced, Recurrent, or Metastatic Endometrial Cancer
The primary purpose of this study is to investigate whether administration of ixabepilone results in superior outcome as assessed by overall survival compared with that achieved with standard chemotherapy (paclitaxel or…
- Trial name
- IXAMPLE2 (NCT00883116)
- Testing
- Ixabepilone, Doxorubicin, Paclitaxel
- Where
- 93 sites in United States, Argentina and 17 more
- Volunteers
- 551 people
- Sponsor
- R-Pharm
Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer
Paclitaxel and Intraperitoneal Carboplatin Followed by Radiation Therapy in Treating Patients With Stage IIIC-IV Uterine Cancer
This pilot, phase II trial studies the side effects and how well paclitaxel given into the vein and carboplatin given directly into the abdominal cavity (intraperitoneally) followed by radiation therapy work in treating patients…
- Conditions
- Endometrial Serous Adenocarcinoma, Stage IIIA Uterine Corpus Cancer, Stage IIIB Uterine Corpus Cancer, Stage IIIC1 Uterine Corpus Cancer
- Trial name
- NCT02112552
- Testing
- Paclitaxel, Carboplatin, 3-Dimensional Conformal Radiation Therapy
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Albert Einstein College of Medicine
Leiomyosarcoma, Uterine Neoplasm
Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma
The purpose of this trial is to study the benefits of giving chemotherapy to women after they have had surgical resection of their primary disease and have no evidence of disease remaining(known as adjuvant therapy).
- Trial name
- NCT00282087
- Testing
- gemcitabine, docetaxel, doxorubicin
- Where
- 12 sites in United States
- Volunteers
- 47 people
- Sponsor
- Sarcoma Alliance for Research through Collaboration
Adult Fibrosarcoma, Adult Leiomyosarcoma
AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma
This phase II trial is studying how well AZD0530 works in treating patients with recurrent locally advanced, or metastatic soft tissue sarcoma.
- Conditions
- Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma
- Trial name
- NCT00659360
- Testing
- saracatinib
- Where
- 4 sites in United States, Canada
- Volunteers
- 17 people
- Sponsor
- National Cancer Institute (NCI)
Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma
Paclitaxel and Carboplatin or Ifosfamide in Treating Patients With Newly Diagnosed, Persistent or Recurrent Uterine, Ovarian, Fallopian Tube, or Peritoneal Cavity Cancer
This randomized phase III trial studies paclitaxel and carboplatin see how well they work compared with paclitaxel and ifosfamide in treating patients with fallopian tube, or peritoneal cavity cancer that is newly diagnosed…
- Conditions
- Mixed Mesodermal (Mullerian) Tumor, Ovarian Carcinosarcoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma
- Trial name
- NCT00954174
- Testing
- Carboplatin, Ifosfamide, Paclitaxel
- Where
- 538 sites in United States, South Korea
- Volunteers
- 637 people
- Sponsor
- GOG Foundation